Articles published by IMVARIA Inc.

IMVARIA’s AI-Powered, Non-Invasive Bronchosolve Solution Meets Primary Endpoints for Lung Cancer Diagnosis in Pivotal VIRTUAL-BRONCH Study

Today 8:30 EDT

From IMVARIA Inc.

Via Business Wire

IMVARIA Awarded Phase I NIH SBIR Grant to Extend the Company’s AI-powered Adjunctive Diagnostic Service into Oncology

September 03, 2025

From IMVARIA Inc.

Via Business Wire

IMVARIA Reports Multi-Site Clinical Experience With FDA-Authorized AI Diagnostic Service for Idiopathic Pulmonary Fibrosis at ATS 2025

May 18, 2025

From IMVARIA Inc.

Via Business Wire

IMVARIA Receives 510(k) Clearance for ScreenDx, a First-of-its-Kind Screening Algorithm to Assess for Interstitial Lung Disease

January 13, 2025

From IMVARIA Inc.

Via Business Wire

IMVARIA Announces FDA De Novo Marketing Authorization of Fibresolve, an AI Biomarker in Lung Fibrosis, and the Adoption of Novel CPT Billing Codes by the American Medical Association

January 16, 2024

From IMVARIA Inc.

Via Business Wire

IMVARIA Enters into Know-how Agreement with Mayo Clinic to Improve the Understanding of Cancer through AI Digital Biomarkers

November 01, 2023

From IMVARIA Inc.

Via Business Wire

IMVARIA Announces Data Demonstrating Company’s Non-Invasive Digital Biomarker for Predicting Mortality in Interstitial Lung Diseases

May 18, 2023

From IMVARIA Inc.

Via Business Wire

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.